Imagine a cancer therapy that revs up the immune system to recognize and destroy cancer, similar to how stepping on the gas pedal revs up a car’s engine to accelerate. Now imagine this treatment also builds immunity to that cancer, preventing it from coming back. That’s the potential we’re seeing in a cancer-fighting antibody anti-OX40, which was developed and tested in humans for the first time at Providence Cancer Center. Anti-OX40 is rapidly gaining traction as an innovative way to potentially treat cancer.
Learn more ›
Types of Cancer Treated with anti-OX40
While anti-OX40 has the potential to improve treatment for any type of cancer, our research and clinical trials to date have focused on:
- Head and neck cancer
- Melanoma (skin cancer)
- Breast cancer
- Colorectal cancer
- Kidney cancer
- Prostate cancer
Our goal is to add anti-OX40 to other treatments to help boost responses in tumors that were previously resistant to immunotherapy.
How OX40 Works
OX40 is a protein with powerful cancer-fighting properties found on the surface of certain T-cells, the white blood cells that help the immune system fight diseases. Providence scientists engineered an antibody to this protein, called anti-OX40, which activates T-cells to attack cancer cells.
Early research results spurred Providence to launch the world’s first clinical trial of anti-OX40 in humans. In that trial, anti-OX40 shrank tumors in 12 of 30 patients studied. Read the study abstract.
In new studies, we are combining anti-OX40 with other treatments that release the brakes on the immune system, in much the same way that anti-OX40 hits the gas, to maximize the activity of immune cells. One study, for example, combines anti-OX40 with stereotactic body radiation therapy (SBRT) in people with metastatic breast cancer.
View a list of our current OX40 clinical trials ›